Navigation Links
BELLUS Health to present at the Rodman and Renshaw 5th Annual Global Healthcare Conference
Date:5/15/2008

Presentation will be Web cast live

LAVAL, QC, May 15 /PRNewswire-FirstCall/ - BELLUS Health Inc. (NASDAQ: BLUS; TSX: BLU, formerly known as Neurochem Inc.) announces today that on Monday, May 19, 2008, Dr. Francesco Bellini, BELLUS Health's Chairman, President and Chief Executive Officer will present BELLUS Health's strategy at the Rodman and Renshaw 5th Annual Global Healthcare Conference to be held at the Le Meridien Beach Plaza Hotel Monte Carlo, Monaco. The presentation will take place at 11:05 A.M. CEST (05:05 A.M. EDT).

The live Web cast of BELLUS Health's presentation (audio and visual) can be accessed at http://www.wsw.com/webcast/rrshq13/blus/. A replay of the presentation will begin three (3) hours after the actual presentation time, and will be available until May 26, 2008. Please access the Web cast approximately 15 minutes before the presentation is scheduled to begin.

About BELLUS Health

BELLUS Health is a global health company focused on the development and commercialization of products to provide innovative health solutions to address critical unmet medical needs.

To Contact BELLUS Health

For additional information on BELLUS Health and its programs, please call the Canada and United States toll-free number 1-877-680-4500 or visit the Web Site at http://www.bellushealth.com.

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond BELLUS Health Inc.'s (formerly known as Neurochem Inc.) control. Such risks include but are not limited to: the impact of general economic
'/>"/>

SOURCE BELLUS Health Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)
2. BELLUS HEALTH reports results for first quarter of fiscal 2008
3. Penn study finds pro-death proteins required to regulate healthy immune function
4. UCLA researchers identify markers that may predict diabetes in still-healthy people
5. Air pollution linked to cardiovascular risk indices in healthy young adults
6. More proof needed of safety and quality of electronic personal health records
7. Health care incentive model offers collaborative approach
8. Loneliness is bad for your health
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Green Tea May Brew Up Healthier Skin
11. For Health Info, Women Often Turn to the Web
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...l needs of patients, families and staff , , SAN...ital, the flagship facility of San Diego County,s ...s completed a multi-tiered expansion to become the...d facility in the region. The new 315,000-square-f...althcare Center, is also the first hospital in San...
(Date:1/8/2009)...the Nemours Center for Childhood Cancer Research (...omedical Research headquartered at the Alfred I. d... secured $1,020,000 in external funding for awards... Florida (Vocus) January 8, 2009-- The researc...r Research (NCCCR), a newly established division o...
(Date:1/8/2009)...ease , , THURSDAY, Jan. 8 (HealthDay New...rican men and women with type 2 diabetes: Snoring ...toms of obstructive sleep apnea, a potentially lif...iabetics. , Based on strong preliminary evidenc... are encouraging physicians to assess their diabet...
(Date:1/8/2009)... to support local programs as part of a nationwide...inn., Jan. 8 Special ...nding to support Project UNIFY as part of Special ...ject UNIFY is an initiative to activate young peop...e school communities where all young people are ag...
Breaking Medicine News(10 mins):Health News:New Sharp Memorial Hospital Features All Private Patient Rooms, Expanded Emergency and Trauma Services and Family Waiting Areas 2Health News:New Sharp Memorial Hospital Features All Private Patient Rooms, Expanded Emergency and Trauma Services and Family Waiting Areas 3Health News:New Sharp Memorial Hospital Features All Private Patient Rooms, Expanded Emergency and Trauma Services and Family Waiting Areas 4Health News:Nemours Center for Childhood Cancer Research Receives Over $1 Million in Grants for Cancer Research in 2008 2Health News:Nemours Center for Childhood Cancer Research Receives Over $1 Million in Grants for Cancer Research in 2008 3Health News:Nemours Center for Childhood Cancer Research Receives Over $1 Million in Grants for Cancer Research in 2008 4Health News:Doctors Urged to Screen Diabetics for Sleep Apnea 2Health News:Doctors Urged to Screen Diabetics for Sleep Apnea 3Health News:Special Olympics Minnesota Launches Project UNIFY to Energize Youth 2
...ce in OK! magazine's list of 'most influential' ce...topped the 'beauty queen' category for her 'refres...ropped haircut, leaving singers Beyonce and Jennif...rding to the BBC, the magazine created a list of 1...
...d a symbol of love continues to enjoy its position... tomb of Mumtaj has charmed many throughout the la...ite. The new list of seven wonders function was ... Lisbon. The announcement was made at a star-studd...
...s display in the public is back again in news, fla...stor claims he is her new found love. Britney h...h her new single status the pop diva has been havi... long back she was snapped flashing her crotch. Th...
...ve caught the imagination of the world. In Singa...007 a date that doesnt repeat itself in a century...he date 7.07.07 a very auspicious day. Jane L...th Chua were dating for nine years before they dec...
Other Medicine News:
(Date:1/5/2009)...RNewswire/ -- Cylene Pharmaceuticals announced tod...of its oral CK2 protein kinase inhibitor, CX-4945,...,s disease, or multiple myeloma. The primary endpo...nation of safety, tolerance and PK properties of C...e II trials. In addition, multiple mechanism-relat...
(Date:12/29/2008)...29 The winner of the 20...on was announced today by Dr. Peter G. Goldschmidt...Institute. , , The winner of the annual award ...er Center -- for its best practice " IND Regulat...s for 1) enhanced human subjects protection, 2) im...
(Date:12/17/2008)... for the first time that normal stem cells can act..., , MEMPHIS, Tenn., Dec. 17 /PRNewswire-USNe...earch Hospital have answered a central question in...e rise to tumors. Stem cells are immature cells th...fferentiated cells that compose the range of body ...
(Date:12/17/2008)...ance, December 17 NicOx,...ositive results of a,pre-specified pooled analysi...,the 301, 302 and 303 pivotal phase 3 studies for ...ignificant reduction in systolic and diastolic blo...0 mg bid over the whole 13 week,period (p<0.00...
Breaking Medicine Technology:Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 32008 Human Research Protection Award Recipients Announced 2Molecular Marker Identifies Normal Stem Cells as Intestinal Tumor Source 2Molecular Marker Identifies Normal Stem Cells as Intestinal Tumor Source 3NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis 2NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis 3NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis 4NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis 5Medco Reports Record Second Quarter 2008 GAAP Diluted EPS 3B Reflects Growth of 34 2 Percent 3B Raises and Narrows 2008 Guidance 24343 1Medco Reports Record Second Quarter 2008 GAAP Diluted EPS 3B Reflects Growth of 34 2 Percent 3B Raises and Narrows 2008 Guidance 24343 2Medco Reports Record Second Quarter 2008 GAAP Diluted EPS 3B Reflects Growth of 34 2 Percent 3B Raises and Narrows 2008 Guidance 24343 3Medco Reports Record Second Quarter 2008 GAAP Diluted EPS 3B Reflects Growth of 34 2 Percent 3B Raises and Narrows 2008 Guidance 24343 4Medco Reports Record Second Quarter 2008 GAAP Diluted EPS 3B Reflects Growth of 34 2 Percent 3B Raises and Narrows 2008 Guidance 24343 5Medco Reports Record Second Quarter 2008 GAAP Diluted EPS 3B Reflects Growth of 34 2 Percent 3B Raises and Narrows 2008 Guidance 24343 6Medco Reports Record Second Quarter 2008 GAAP Diluted EPS 3B Reflects Growth of 34 2 Percent 3B Raises and Narrows 2008 Guidance 24343 7Medco Reports Record Second Quarter 2008 GAAP Diluted EPS 3B Reflects Growth of 34 2 Percent 3B Raises and Narrows 2008 Guidance 24343 8Medco Reports Record Second Quarter 2008 GAAP Diluted EPS 3B Reflects Growth of 34 2 Percent 3B Raises and Narrows 2008 Guidance 24343 9Medco Reports Record Second Quarter 2008 GAAP Diluted EPS 3B Reflects Growth of 34 2 Percent 3B Raises and Narrows 2008 Guidance 24343 10Medco Reports Record Second Quarter 2008 GAAP Diluted EPS 3B Reflects Growth of 34 2 Percent 3B Raises and Narrows 2008 Guidance 24343 11Medco Reports Record Second Quarter 2008 GAAP Diluted EPS 3B Reflects Growth of 34 2 Percent 3B Raises and Narrows 2008 Guidance 24343 12Medco Reports Record Second Quarter 2008 GAAP Diluted EPS 3B Reflects Growth of 34 2 Percent 3B Raises and Narrows 2008 Guidance 24343 13Medco Reports Record Second Quarter 2008 GAAP Diluted EPS 3B Reflects Growth of 34 2 Percent 3B Raises and Narrows 2008 Guidance 24343 14Medco Reports Record Second Quarter 2008 GAAP Diluted EPS 3B Reflects Growth of 34 2 Percent 3B Raises and Narrows 2008 Guidance 24343 15Medco Reports Record Second Quarter 2008 GAAP Diluted EPS 3B Reflects Growth of 34 2 Percent 3B Raises and Narrows 2008 Guidance 24343 16Medco Reports Record Second Quarter 2008 GAAP Diluted EPS 3B Reflects Growth of 34 2 Percent 3B Raises and Narrows 2008 Guidance 24343 17Medco Reports Record Second Quarter 2008 GAAP Diluted EPS 3B Reflects Growth of 34 2 Percent 3B Raises and Narrows 2008 Guidance 24343 18Medco Reports Record Second Quarter 2008 GAAP Diluted EPS 3B Reflects Growth of 34 2 Percent 3B Raises and Narrows 2008 Guidance 24343 19Medco Reports Record Second Quarter 2008 GAAP Diluted EPS 3B Reflects Growth of 34 2 Percent 3B Raises and Narrows 2008 Guidance 24343 20Medco Reports Record Second Quarter 2008 GAAP Diluted EPS 3B Reflects Growth of 34 2 Percent 3B Raises and Narrows 2008 Guidance 24343 21Medco Reports Record Second Quarter 2008 GAAP Diluted EPS 3B Reflects Growth of 34 2 Percent 3B Raises and Narrows 2008 Guidance 24343 22Medco Reports Record Second Quarter 2008 GAAP Diluted EPS 3B Reflects Growth of 34 2 Percent 3B Raises and Narrows 2008 Guidance 24343 23Medco Reports Record Second Quarter 2008 GAAP Diluted EPS 3B Reflects Growth of 34 2 Percent 3B Raises and Narrows 2008 Guidance 24343 24Medco Reports Record Second Quarter 2008 GAAP Diluted EPS 3B Reflects Growth of 34 2 Percent 3B Raises and Narrows 2008 Guidance 24343 25Medco Reports Record Second Quarter 2008 GAAP Diluted EPS 3B Reflects Growth of 34 2 Percent 3B Raises and Narrows 2008 Guidance 24343 26Medco Reports Record Second Quarter 2008 GAAP Diluted EPS 3B Reflects Growth of 34 2 Percent 3B Raises and Narrows 2008 Guidance 24343 27Medco Reports Record Second Quarter 2008 GAAP Diluted EPS 3B Reflects Growth of 34 2 Percent 3B Raises and Narrows 2008 Guidance 24343 28Medco Reports Record Second Quarter 2008 GAAP Diluted EPS 3B Reflects Growth of 34 2 Percent 3B Raises and Narrows 2008 Guidance 24343 29Orchid Cellmark To Announce Second Quarter 2008 Financial Results on July 31 2008 24338 1Orchid Cellmark To Announce Second Quarter 2008 Financial Results on July 31 2008 24338 2United Therapeutics to Announce Second Quarter 2008 Financial Results Before Market Open on Thursday July 31 2008 6711 1STAAR Surgicals Collamer 28R 29 IOL and Elastimide 28R 29 IOL Each Recognized with New Technology Intraocular Lens Classification 24334 1STAAR Surgicals Collamer 28R 29 IOL and Elastimide 28R 29 IOL Each Recognized with New Technology Intraocular Lens Classification 24334 2STAAR Surgicals Collamer 28R 29 IOL and Elastimide 28R 29 IOL Each Recognized with New Technology Intraocular Lens Classification 24334 3STAAR Surgicals Collamer 28R 29 IOL and Elastimide 28R 29 IOL Each Recognized with New Technology Intraocular Lens Classification 24334 4
...BRISBANE, Australia, March 12, 2007: Progen Indust...o announce that its PI-88,Phase II liver cancer da...tation by the European Association for the Study o... the results of this liver,cancer trial at the Ame...l Meeting 2007. , ,In expectation of having final...
...SCHLIEREN (Zurich), Switzerland, March 13, 2007 -,...ositive results,from a phase IIa study with CYT003... the treatment of allergic diseases. The study,inc...allergic,rhinitis due to grass pollen allergy (hay...etting the safety, tolerability and,exploratory ef...
Other Medicine Technology:PI-88 Data to be Presented at Key International Conferences 2PI-88 Data to be Presented at Key International Conferences 3Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 2Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 3Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 4Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 5Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 6Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 7
Reservoir, High Profile, Single Well, 384ch-format, Pyramid Bottom, 282mL Available Sterile
...nd affordable alternative for diagnostic assays an...sable manifold, the StatMatic I provides continuou...es. The eight-port manifold, designed for 96-well ...0, 250, or 300mL with well-to-well accuracy of 5% ...
The 402 Dilutor-Dispenser is designed to transfer liquids for various applications in the clinical, biological, and chemical fields with the same reliability and performance as Gilsons other manual l
...ntact dispensing technique that couples a high pre...e stepper motor. synQUAD dispenses a precise nanol... or membranes. At 100 nL dispense volume per well,... An 8-channel synQUAD system dispenses 100 nL into...
Medicine Products: